Top Midday Gainers

MT Newswires Live07-08

Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.

Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.

MeiraGTx (MGTX) has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.

Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.

Tvardi Therapeutics (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design.

Shares soared 47% as intraday trading volume catapulted to over 56.7 million from a daily average of about 162,000.

Price: 525.34, Change: -4.25, Percent Change: -0.80

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649338934?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 01:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649338934","market":"sh","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.</p><p>Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.</p><p>MeiraGTx (MGTX) has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.</p><p>Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.</p><p>Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design.</p><p>Shares soared 47% as intraday trading volume catapulted to over 56.7 million from a daily average of about 162,000.</p><p>Price: 525.34, Change: -4.25, Percent Change: -0.80</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-08 01:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.</p><p>Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.</p><p>MeiraGTx (MGTX) has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.</p><p>Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.</p><p>Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design.</p><p>Shares soared 47% as intraday trading volume catapulted to over 56.7 million from a daily average of about 162,000.</p><p>Price: 525.34, Change: -4.25, Percent Change: -0.80</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002270589.USD","symbol_name":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649338934","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649338934","pubTimestamp":1783445779,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vertex Pharmaceuticals  and Crinetics Pharmaceuticals  said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.MeiraGTx  has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.Tvardi Therapeutics  said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4567":"ESG概念","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4533":"AQR资本管理(全球第二大对冲基金)","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IBB":"生物科技指数ETF-iShares Nasdaq","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BIB":"Ultra纳斯达克生物科","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","IDNA":"iShares Genomics Immunology and Healthcare ETF","TVRD":"Tvardi Therapeutics Inc","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","MGTX":"Meiragtx Holdings Plc","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BBH":"VanEck Biotech ETF","CRNX":"Crinetics Pharmaceuticals Inc.","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","VRTX":"福泰制药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4532":"文艺复兴科技持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGTX":1,"BBH":0.6,"CRNX":1,"IBB":0.6,"VRTX":1,"IBBQ":0.6,"BIB":0.6,"IDNA":0.6,"PBE":0.6,"TVRD":1},"content_text":"Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reached an agreement for Vertex to buy Crinetics for $85 per share in cash. The deal has a total equity value of about $10 billion and is expected to close in Q3, the companies said.Shares of Crinetics almost doubled amid a surge in intraday trading volume to over 67.1 million from a daily average of roughly 1.30 million.MeiraGTx (MGTX) has signed a deal under which Oberland Capital Management has agreed to invest up to $400 million in the company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity, it said Tuesday.Shares jumped 8.2% following an increase in intraday trading volume to over 1.01 million from a daily average of about 987,000.Tvardi Therapeutics (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design.Shares soared 47% as intraday trading volume catapulted to over 56.7 million from a daily average of about 162,000.Price: 525.34, Change: -4.25, Percent Change: -0.80","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649338934","isCrawlerRequest":true}